BioCryst Pharmaceuticals Inc. (BCRX)

2.68
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 2.68
Open 2.67
Day Low/High 2.63 / 2.73
52 Wk Low/High 2.54 / 9.95
Volume 876.56K
Avg Volume 2.37M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 286.03M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
'Mad Money' Lightning Round: Buy Enbridge Energy Partners

'Mad Money' Lightning Round: Buy Enbridge Energy Partners

Cramer isn't excited by Yahoo!, would buy more Xcel Energy and likes Cisco over Arris Group.

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Despite the many strides the market has made since 2000, critics are once again calling the Nasdaq overvalued and in 'bubble' territory. Cramer details why they're wrong.

BioCryst Pharmaceuticals Stock Sees Short Interest Move 10% Higher

BioCryst Pharmaceuticals Stock Sees Short Interest Move 10% Higher

The most recent short interest data has been released by the NASDAQ for the 01/30/2015 settlement date, which shows a 1,102,518 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,060,331, an increase of 10.06% since 01/15/2015.

First Week of February 20th Options Trading For BioCryst Pharmaceuticals (BCRX)

First Week of February 20th Options Trading For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options become available this week, for the February 20th expiration.

First Week of BCRX September 18th Options Trading

First Week of BCRX September 18th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield

'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield

Cramer is skittish on Sanofi, can't recommend C&J Energy Services and doesn't want you in Annaly Capital.

Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity

Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity

A day's rest from the selling in oil will allow investors, analysts and oil companies themselves some time to assess their situations, Cramer says.

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

BCRX Crosses Below Key Moving Average Level

BCRX Crosses Below Key Moving Average Level

In trading on Wednesday, shares of BioCryst Pharmaceuticals, Inc. crossed below their 200 day moving average of $11.03, changing hands as low as $10.88 per share.

Ebola Linked Names Rise Again Amid Broader Market Sell-Off

Ebola Linked Names Rise Again Amid Broader Market Sell-Off

Shares of companies leveraged to Ebola are rising again after a second health care worker in the U.S. tested positive for the illness.

Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)

Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

Lakeland Industries Continues To Surge Amid Ebola Fears

Lakeland Industries Continues To Surge Amid Ebola Fears

Shares of Lakeland Industries, which supplies protective clothing to the Centers for Disease Control and other governmental agencies, are soaring amid continued fears over the Ebola outbreak...

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.

TheStreet Quant Rating: D- (Sell)